Healthcare and Pharmaceutical Sector

The Food and Drug Administration approved Revolution Medicines' Rasonque, known generically as daraxonrasib, as the first targeted therapy for the most common form of advanced pancreatic cancer. The once-daily oral RAS inhibitor achieved a median overall survival of 13.2 months in a clinical trial of 500 adult patients, compared to 6.7 months for standard chemotherapy. Rasonque targets the RAS protein, a genetic driver present in 90% to 100% of pancreatic adenocarcinomas that has historically resisted pharmaceutical intervention. The agency granted the approval 6.5 months ahead of its Prescription Drug User Fee Act deadline using its National Priority Voucher pilot program. Revolution Medicines secured the clearance following clinical data that also demonstrated doubled progression-free survival in pretreated patients.

Sword Health has agreed to acquire mental health company Headspace through a cash purchase of its parent company, OrangeDot. The transaction combines two digital health unicorns and is scheduled to become effective on September 14, following a material change filing submitted to the Massachusetts Health Policy Commission on July 22. Sword Health recently raised $40 million in 2025 at a valuation exceeding $4 billion, bringing its total funding to $493 million. The acquisition broadens Sword Health's platform beyond its core virtual physical therapy offering into mental health services. Financial terms of the transaction were not disclosed in the regulatory paperwork.

Akeso and partner Summit Therapeutics reported that their PD-1xVEGF bispecific antibody ivonescimab met its primary overall survival endpoint in a China-only Phase 3 trial for advanced biliary tract cancer. In the Harmoni-GI1 trial, ivonescimab combined with chemotherapy outperformed AstraZeneca's Imfinzi plus chemotherapy regimen. The trial also met its key secondary endpoints of progression-free survival and objective response rate. Akeso enrolled nearly 700 participants in the trial over 11 months. Detailed data will be presented at the European Society for Medical Oncology annual meeting in October.

Bristol Myers Squibb terminated its manufacturing partnership with cell therapy startup Cellares after determining that the Cell Shuttle platform could not produce its CAR-T therapy, Breyanzi, at commercial scale. The cancelled 2024 agreement was worth up to $380 million and reserved manufacturing capacity across the U.S., the European Union, and Japan. Cellares disputed the assessment, stating the platform has already manufactured a Good Manufacturing Practice-compliant product in an FDA-regulated clinical program. The lost pharmaceutical contract forced Cellares to restructure and file a notice to lay off about 100 employees at its South San Francisco facility on October 20. Breyanzi generated $1.36 billion in sales in 2025, though Bristol Myers' decision applies exclusively to that therapy and its approved manufacturing process.

Boston Scientific disclosed a cyberattack on Wednesday that hobbled its global operations and cut off the information systems used to process and ship customer orders. The medical device maker uncovered the breach on Tuesday and brought in outside cybersecurity experts to contain the threat while recovery efforts crawl forward without a known timeline. Shares dropped between 4% and 6% in early trading following the news. The disruption piles operational friction onto a manufacturer already wrestling with a weak first-quarter profit forecast and a global restructuring program slated to run through 2029. Evercore ISI analyst Vijay Kumar estimated that a recovery timeline similar to peer Stryker's recent incident could shave 600 to 700 basis points off third-quarter revenue. The healthcare sector accounted for 22% of disclosed cyberattacks in 2025, making medical technology a primary target for threat actors.

Biohaven is selling the global rights to its most advanced experimental medicine, the focal epilepsy treatment opakalim, to South Korea's SK Biopharmaceuticals in a transaction valued at up to $795 million. Under the agreement, SK will pay $350 million upfront and another $50 million next year, alongside up to $150 million in development and regulatory milestone payments. SK will also assume up to $245 million in obligations owed to opakalim's previous owner, Knopp Biosciences. For Biohaven, the deal injects non-dilutive capital into a balance sheet strained by research setbacks and a dwindling cash reserve, while offloading development risk ahead of topline results from the Rise3 trial due before the end of the year. The partnership leaves Biohaven eligible for royalties ranging from the mid-teens to low twenties if opakalim reaches the market, though analysts note it surrenders the immediate upside of commercializing its most mature asset.

Spyre Therapeutics is dropping monotherapy development for its anti-TL1A antibody SPY072 in rheumatoid arthritis after midstage trial results missed internal efficacy benchmarks. At Week 12 of the phase 2 trial, SPY072 delivered placebo-adjusted Disease Activity Score reductions of 1.5 and 1.9 points on high and low doses, against a control arm drop of 1.3 points. Only the low dose achieved statistical significance. The data also fell short of targeted placebo-adjusted improvements across ACR20, ACR50, and ACR70 metrics. Spyre's stock traded down 12.4% to $93.99 in premarket trading following the announcement, down from a Tuesday close of $107.36. The biotech plans to pivot its TL1A development strategy toward psoriatic arthritis, axial spondyloarthritis, and combination therapies.

SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.